

DRUG UTILIZATION REVIEW BOARD MEETING

Wednesday, April 15, 2020

AGENDA

Join Webex Meeting

Meeting number (access code): 282 119 546

Join from a video system or application

Dial [282119546@stateofmo.webex.com](tel:282119546)

You can also dial 173.243.2.68 and enter your meeting number.

Join by phone

Tap to call in from a mobile device (attendees only)

[1-650-479-3207](tel:16504793207) Call-in toll number (US/Canada)

[Global call-in numbers](#)

10:00 - 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15 - 10:25	Pharmacy Program/ Budget Update	Elizabeth Short
10:20 – 1:00	Review of Prior Authorization Meeting and Public Hearing	Josh Moore

Clinical Edits

- I. **Acne or Rosacea – Select Topical Agents**
- II. **Clobazam Agents**
- III. **DMD**
- IV. **Epidiolex**
- V. **Galafold**
- VI. **Givlaari**
- VII. **Megestrol Acetate**
- VIII. **Nocturnal Polyuria**
- IX. **Reblozyl**
- X. **Sickle Cell Disease**
- XI. **Spravato**
- XII. **Systemic Antifungals**

Preferred Drug List (PDL)

- I. **Actinic Keratosis Agents - Topical**
- II. **Androgenic Agents**
- III. **Antibiotics – Inhaled Agents**
- IV. **Antifungal Agents – Oral**
- V. **Antifungal Agents – Topical**

- VI. Antihistamines – Intranasal
- VII. Antihistamines – Ophthalmic
- VIII. Antihistamines/Decongestant Combinations – Low Sedating (2nd Generation)
- IX. Antiparasitic Agents – Topical
- X. Antiviral Agents – Herpes Oral
- XI. Antiviral Agents – Topical
- XII. Atopic Dermatitis Agents – Immunomodulators
- XIII. Benzoyl Peroxide/Antibiotic Combinations
- XIV. Beta-Adrenergic Agents – Long Acting
- XV. Beta-Adrenergic Agents – Nebulized
- XVI. Beta-Adrenergic Agents – Short Acting
- XVII. COPD Agents
- XVIII. Corticosteroids – Inhaled
- XIX. Corticosteroids – Ophthalmic “Soft” Steroids
- XX. Corticosteroids – Topical
- XXI. Corticosteroids and Rhinitis Agents – Intranasal
- XXII. Cough and Cold Preparations
- XXIII. Epinephrine Self-Injectable Agents
- XXIV. Fluoroquinolones – Ophthalmic
- XXV. Fluoroquinolones – Otic
- XXVI. Glaucoma Agents
- XXVII. Leukotriene Receptor Modifiers
- XXVIII. Mast Cell Stabilizers – Ophthalmic
- XXIX. NSAIDs – Ophthalmic
- XXX. Pancreatic Enzyme Agents
- XXXI. Psoriasis Agents – Oral
- XXXII. Psoriasis Agents – Topical
- XXXIII. Retinoids – Topical
- XXXIV. Ulcerative Colitis Agents – Oral
- XXXV. Ulcerative Colitis Agents - Rectal

1:00

LUNCH

1:00-2:00

Program Utilization Information - Conduent Update

Olivia Rush

Other Business

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

- *Move to close under Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*

2:00-3:00 **Executive Session**

- Patient Profile Reviews